ASH 2023 | Identifying predictors for ruxolitinib treatment-related thrombocytopenia in patients with MF
Douglas Tremblay, MD, Icahn School of Medicine at Mount Sinai, New York, NY, discusses a retrospective cohort study which aimed to identify the predictors of thrombocytopenia in patients with myelofibrosis (MF) treated with ruxolitinib. The primary factor which was predictive of thrombocytopenia development was a low baseline platelet count, and no molecular or mutational predictors were determined. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Consultancy: Cogent Biosciences, GSK, Sierra Oncology, AbbVie, Novartis, CTI Biopharma
Research Funding: CTI Biopharma, Astellas Pharma, Gilead
